Regulus Therapeutics this week released new preclinical data showing that microRNA-21 is implicated in the fibrotic kidney condition Alport syndrome and indicated that the program could likely yield its next clinical candidate.
Regulus Therapeutics this week announced that AstraZeneca has selected an undisclosed oncology target under the companies' ongoing partnership to develop microRNA-targeting drugs for oncology and cardiovascular and metabolic diseases.
Regulus Therapeutics remains on track to filing an investigational new drug application for its microRNA-targeting hepatitis C treatment RG-101 next year, with a second candidate — likely for fibrosis or cancer — to be added to the company's formal pipeline before the end of 2013
Regulus Therapeutics said this week that it has priced the public offering of 4.5 million shares of its common stock at $9.50 each.
As of midday Wednesday, Regulus’ stock was trading around $10.05 a share.